USOR 20396_AZ_DESTINY | Maryland Oncology Hematology USOR 20396_AZ_DESTINY – Maryland Oncology Hematology

USOR 20396_AZ_DESTINY

Trial Information

Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)



Sponsor: AstraZeneca

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast Cancer

Investigator

Ackerman, Courtney

Sponsor

AstraZeneca
« Clinical Trails Main

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology